Stocks · News reference
Raymond James has initiated coverage on Benitec Biopharma Inc. with an "Outperform" rating and a price target of $14.00 per share.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Benitec Biopharma reported positive interim results from its Phase 1b/2a study of BB-301, showing robust and durable improvements in swallowing function for patients with Oculopharyngeal Muscular Dystrophy (OPMD).
Filed: 2026-10-28 AccNo: 0001193125-26-435159 Size: 214 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.